Aktienanalyse zu Globus Medical Inc (GMED)GMEDGlobus Medical Inc

Globus Medical, Inc. is a global musculoskeletal company. The Company provides education and clinical support, and advanced care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. The Company offers a comprehensive portfolio of technologies that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its segments include Musculoskeletal Solutions and Enabling Technologies. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, surgical instruments, spinal cord stimulation treatment therapy, and neuromonitoring services, used in an expansive range of spinal, orthopedic and neurosurgical procedures. Its Enabling Technologies are comprised of imaging, navigation and robotics (INR) solutions for assisted surgery, which are advanced computer-assisted intelligent systems designed to enhance a surgeon’s capabilities. The Company also provides digital healthcare solutions. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Globus Medical Inc is a good buy right now, with a current price of $82.97 and a forward P/E ratio of 18.18, indicating potential for growth. The company has raised its EPS guidance to a range of $4.95 to $5.05, reflecting management's confidence in future profitability despite a recent decline in net income. However, insider selling has increased by 389.20%, which could signal caution for potential investors.

13 analysts cover GMED: 5 rate it Buy, 7 Hold and 1 Sell. The average price target is 101.00.